Full Breakdown
HHS Draft Policy Would Permit Compounding of Six Unapproved Peptide Injections
By Drooid · · How we work
In this breakdown
01
Core Policy Announcement (October 28, 2026)
On October 28, 2026 the U.S. Department of Health and Human Services (HHS) released draft guidance that would allow licensed compounding pharmacies to prepare six peptide substances—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500—without FDA approval. The guidance directs the FDA not to enforce existing prohibitions against compounding these peptides and requires pharmacies to use FDA-registered ingredient manufacturers, conduct purity testing, and report adverse events.
02
Background & Context
- In 2023 the FDA placed BPC-157, TB-500 and other peptides on a list of substances that should not be compounded because of reported risks such as tumor growth, kidney damage, and allergic reactions.
- The 2012 fungal meningitis outbreak linked to a Massachusetts compounding pharmacy spurred the FDA to tighten oversight of compounded drugs.
- An outside advisory panel convened by HHS in July voted to lift limits on the six peptides, a recommendation that the agency cited in the new draft despite opposition from FDA scientific staff.
Visual evidence
Images from the story
03
Peptides Targeted and Market Potential
The draft policy focuses on the following six injectable peptides:
Swipe across the table to see all columns.
| Peptide | Notable claimed uses (wellness-industry marketing) |
|---|---|
| BPC-157 | Muscle injury healing, tissue repair |
| Epitalon | Anti-aging, sleep regulation |
| KPV | Anti-inflammatory, pain relief |
| MOTS-c | Metabolic support, endurance |
| Semax | Cognitive enhancement, neuroprotection |
| TB-500 | Tissue regeneration, injury recovery |
Wall Street analysts estimate that the U.S. market for wellness peptides could exceed $2 billion if the policy is finalized.
04
Official Statements & Responses
- Robert F. framed the action as a “more controlled alternative” to black-market peptide sales.
- FDA scientists warned that the six peptides lack sufficient evidence of safety and effectiveness, and that the agency’s legal authority to enforce the proposed safeguards is limited.
05
Criticism & Opposition
- FDA scientific staffers, largely excluded from drafting the guidance, warned that the policy could undermine the agency’s mission to keep unsafe products off the market.
- The Alliance for Pharmacy Compounding highlighted uncertainties about when the policy would take effect and how it would intersect with state pharmacy boards.
06
Conflicting Reports & Gaps
- Legal authority: Lurie contends that the FDA lacks statutory power to enforce the draft’s pharmacy-level requirements, while other sources note that HHS can delegate enforcement to the FDA.
- Implementation timeline: HHS officials have not specified an exact start date, and the draft does not clarify how state boards will coordinate with federal requirements.
07
Verbatim Quotes
- “This is a wink and nod to the MAHA faithful in the hope that they’ll show up at the polls,” — Peter Lurie, former FDA official
- “By allowing limited compounding of the substances addressed in this guidance under appropriate safeguards, the policy provides patients with a more controlled alternative,” — Robert F. Kennedy Jr., health secretary
08
What’s Next
The draft guidance will be open for public comment for two weeks beginning the Friday after its release. The policy will remain in effect until the FDA issues a final rule on compounded peptides.